Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PIK3CA E545K

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

PIK3CA mutation + HR positive (16)

PIK3CA mutation + ER positive (10)

PIK3CA mutation + PTEN deletion (5)

ER positive + PIK3CA H1047R (3)

HR-positive + PIK3CA wild-type (3)

PIK3CA exon 20 mutation + HR positive (3)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

PIK3CA H1047R + PIK3C2B amplification (2)

PIK3CA mutation + ER negative (2)

PIK3CA mutation + HR negative (2)

PIK3CA mutation + MSI-L/dMMR (2)

TMB-H + PIK3CA mutation (2)

CCNE1 overexpression + PIK3CA muattion + ER positive (1)

CCNE2 overexpression + PIK3CA mutation + ER positive (1)

EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)

EGFR exon 19 deletion + PTEN deletion + PIK3CA overexpression (1)

ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)

ER positive + ESR1 mutation + PIK3CA mutation (1)

ESR1 mutation + PIK3CA mutation + HR positive (1)

HR positive + PIK3CA exon 10 mutation (1)

HRAS overexpression + PIK3CA amplification (1)

HRAS overexpression + PIK3CA mutation (1)

KRAS mutation + PIK3CA wild-type (1)

MET amplification + PIK3CA mutation (1)

MTAP deletion + PIK3CA mutation (1)

MYB fusion + PIK3CA mutation (1)

PD-L1 expression + PIK3CA mutation (1)

PIK3CA E542K + HR positive (1)

PIK3CA E542Q + TMB-H + MSI-H/dMMR (1)

PIK3CA H1047R + HER-2 amplification (1)

PIK3CA R88Q + PD-L1 expression (1)

PIK3CA amplification + PIK3CA mutation + HR positive (1)

PIK3CA exon 7 mutation + HR positive (1)

PIK3CA exon 9 mutation + HR positive (1)

PIK3CA mutation + ALK fusion (1)

PIK3CA mutation + ALK positive (1)

PIK3CA mutation + BRAF wild-type (1)

PIK3CA mutation + ESR1 wild-type (1)

PIK3CA mutation + HER-2 amplification (1)

PIK3CA mutation + HER-2 positive (1)

PIK3CA mutation + HR positive + HER-2 negative (1)

PIK3CA mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

PIK3CA mutation + PTEN underexpression (1)

PIK3CA mutation + RAS wild-type (1)

PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

PIK3CA wild-type+ ESR1 wild-type (1)

SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)

ER negative + HER-2 positive + PIK3CA H1047R (0)

MYB fusion + PIK3CA amplification (0)

PIK3CA E453K + HER-2 positive (0)

PIK3CA E542K + HER-2 positive (0)

PIK3CA E542Q + HER-2 positive (0)

PIK3CA H1047L + HER-2 positive (0)

PIK3CA H1047R + HER-2 positive (0)

PIK3CA N345K + HER-2 positive (0)

PIK3CA amplification + HER-2 positive (0)

PIK3CA amplification + PTEN deletion (0)

PIK3CA mutation + ER negative + PGR positive (0)

PIK3CA mutation + PTEN expression (0)

PIK3CA mutation + TMB-L + MSI-L/dMMR (0)

PIK3CA mutation + HR positive (16)

PIK3CA mutation + ER positive (10)

PIK3CA mutation + PTEN deletion (5)

ER positive + PIK3CA H1047R (3)

HR-positive + PIK3CA wild-type (3)

PIK3CA exon 20 mutation + HR positive (3)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

PIK3CA H1047R + PIK3C2B amplification (2)

PIK3CA mutation + ER negative (2)

PIK3CA mutation + HR negative (2)

PIK3CA mutation + MSI-L/dMMR (2)

TMB-H + PIK3CA mutation (2)

CCNE1 overexpression + PIK3CA muattion + ER positive (1)

CCNE2 overexpression + PIK3CA mutation + ER positive (1)

EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)

EGFR exon 19 deletion + PTEN deletion + PIK3CA overexpression (1)

ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)

ER positive + ESR1 mutation + PIK3CA mutation (1)

ESR1 mutation + PIK3CA mutation + HR positive (1)

HR positive + PIK3CA exon 10 mutation (1)

HRAS overexpression + PIK3CA amplification (1)

HRAS overexpression + PIK3CA mutation (1)

KRAS mutation + PIK3CA wild-type (1)

MET amplification + PIK3CA mutation (1)

MTAP deletion + PIK3CA mutation (1)

MYB fusion + PIK3CA mutation (1)

PD-L1 expression + PIK3CA mutation (1)

PIK3CA E542K + HR positive (1)

PIK3CA E542Q + TMB-H + MSI-H/dMMR (1)

PIK3CA H1047R + HER-2 amplification (1)

PIK3CA R88Q + PD-L1 expression (1)

PIK3CA amplification + PIK3CA mutation + HR positive (1)

PIK3CA exon 7 mutation + HR positive (1)

PIK3CA exon 9 mutation + HR positive (1)

PIK3CA mutation + ALK fusion (1)

PIK3CA mutation + ALK positive (1)

PIK3CA mutation + BRAF wild-type (1)

PIK3CA mutation + ESR1 wild-type (1)

PIK3CA mutation + HER-2 amplification (1)

PIK3CA mutation + HER-2 positive (1)

PIK3CA mutation + HR positive + HER-2 negative (1)

PIK3CA mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

PIK3CA mutation + PTEN underexpression (1)

PIK3CA mutation + RAS wild-type (1)

PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)

PIK3CA wild-type+ ESR1 wild-type (1)

SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)

ER negative + HER-2 positive + PIK3CA H1047R (0)

MYB fusion + PIK3CA amplification (0)

PIK3CA E453K + HER-2 positive (0)

PIK3CA E542K + HER-2 positive (0)

PIK3CA E542Q + HER-2 positive (0)

PIK3CA H1047L + HER-2 positive (0)

PIK3CA H1047R + HER-2 positive (0)

PIK3CA N345K + HER-2 positive (0)

PIK3CA amplification + HER-2 positive (0)

PIK3CA amplification + PTEN deletion (0)

PIK3CA mutation + ER negative + PGR positive (0)

PIK3CA mutation + PTEN expression (0)

PIK3CA mutation + TMB-L + MSI-L/dMMR (0)

›

Related tests:

FoundationOne® CDx (110)

FoundationOne® Liquid CDx (21)

therascreen® PIK3CA RGQ PCR Kit (3)

FoundationOne® CDx (110)

FoundationOne® Liquid CDx (21)

therascreen® PIK3CA RGQ PCR Kit (3)

PIK3CA E545K	Colorectal Cancer	PIK3CA E545K	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
PIK3CA E545K	Non Small Cell Lung Cancer	PIK3CA E545K	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
PIK3CA E545K	Ovarian Cancer	PIK3CA E545K	Ovarian Cancer	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3
PIK3CA E545K	Breast Cancer	PIK3CA E545K	Breast Cancer	olaparib + durvalumab + capivasertib Sensitive: C3 – Early Trials olaparib + durvalumab + capivasertib Sensitive : C3	olaparib + durvalumab + capivasertib Sensitive: C3 – Early Trials olaparib + durvalumab + capivasertib Sensitive : C3
PIK3CA E545K	Gastric Cancer	PIK3CA E545K	Gastric Cancer	CYH33 Sensitive: C4 – Case Studies CYH33 Sensitive : C4	CYH33 Sensitive: C4 – Case Studies CYH33 Sensitive : C4
PIK3CA E545K	Breast Cancer	PIK3CA E545K	Breast Cancer	CYH33 Sensitive: C4 – Case Studies CYH33 Sensitive : C4	CYH33 Sensitive: C4 – Case Studies CYH33 Sensitive : C4
PIK3CA E545K	Ovarian Cancer	PIK3CA E545K	Ovarian Cancer	CYH33 Sensitive: C4 – Case Studies CYH33 Sensitive : C4	CYH33 Sensitive: C4 – Case Studies CYH33 Sensitive : C4
PIK3CA E545K	HER2 Negative Breast Cancer	PIK3CA E545K	HER2 Negative Breast Cancer	CYH33 Sensitive: C4 – Case Studies CYH33 Sensitive : C4	CYH33 Sensitive: C4 – Case Studies CYH33 Sensitive : C4
PIK3CA E545K	Cervical Cancer	PIK3CA E545K	Cervical Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
PIK3CA E545K	Breast Cancer	PIK3CA E545K	Breast Cancer	GDC-0941 Sensitive: D – Preclinical GDC-0941 Sensitive : D	GDC-0941 Sensitive: D – Preclinical GDC-0941 Sensitive : D
PIK3CA E545K	Breast Cancer	PIK3CA E545K	Breast Cancer	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
PIK3CA E545K	Breast Cancer	PIK3CA E545K	Breast Cancer	lapatinib Sensitive: D – Preclinical lapatinib Sensitive : D	lapatinib Sensitive: D – Preclinical lapatinib Sensitive : D
PIK3CA E545K	HER2 Positive Breast Cancer	PIK3CA E545K	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: D – Preclinical ado-trastuzumab emtansine Sensitive : D	ado-trastuzumab emtansine Sensitive: D – Preclinical ado-trastuzumab emtansine Sensitive : D
PIK3CA E545K	Breast Cancer	PIK3CA E545K	Breast Cancer	trastuzumab + lapatinib Resistant: D – Preclinical trastuzumab + lapatinib Resistant : D	trastuzumab + lapatinib Resistant: D – Preclinical trastuzumab + lapatinib Resistant : D
PIK3CA E545K	Thyroid Gland Papillary Carcinoma	PIK3CA E545K	Thyroid Gland Papillary Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	BMS-722782 Resistant: D – Preclinical BMS-722782 Resistant : D	BMS-722782 Resistant: D – Preclinical BMS-722782 Resistant : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	trametinib Resistant: D – Preclinical trametinib Resistant : D	trametinib Resistant: D – Preclinical trametinib Resistant : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	GDC-0941 Resistant: D – Preclinical GDC-0941 Resistant : D	GDC-0941 Resistant: D – Preclinical GDC-0941 Resistant : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D	GDC-0032 Sensitive: D – Preclinical GDC-0032 Sensitive : D
PIK3CA E545K	Melanoma	PIK3CA E545K	Melanoma	vemurafenib Resistant: D – Preclinical vemurafenib Resistant : D	vemurafenib Resistant: D – Preclinical vemurafenib Resistant : D
PIK3CA E545K	Hepatocellular Cancer	PIK3CA E545K	Hepatocellular Cancer	alpelisib Sensitive: D – Preclinical alpelisib Sensitive : D	alpelisib Sensitive: D – Preclinical alpelisib Sensitive : D
PIK3CA E545K	Hormone Receptor Positive Breast Cancer	PIK3CA E545K	Hormone Receptor Positive Breast Cancer	abemaciclib + RLY-2608 Sensitive: D – Preclinical abemaciclib + RLY-2608 Sensitive : D	abemaciclib + RLY-2608 Sensitive: D – Preclinical abemaciclib + RLY-2608 Sensitive : D
PIK3CA E545K	Hormone Receptor Positive Breast Cancer	PIK3CA E545K	Hormone Receptor Positive Breast Cancer	palbociclib + RLY-2608 Sensitive: D – Preclinical palbociclib + RLY-2608 Sensitive : D	palbociclib + RLY-2608 Sensitive: D – Preclinical palbociclib + RLY-2608 Sensitive : D
PIK3CA E545K	Hormone Receptor Positive Breast Cancer	PIK3CA E545K	Hormone Receptor Positive Breast Cancer	RLY-2608 Resistant: D – Preclinical RLY-2608 Resistant : D	RLY-2608 Resistant: D – Preclinical RLY-2608 Resistant : D